Market News & Trends
$100 Billion of Revenues up for Grabs for Drug Manufacturers by 2020 as Patents for Key Biologics Expire
Although complexities inherent in biological drug manufacturing are creating barriers for further expansion of the biosimilars market, imminent patent expiries of key biologics are set…
Ompi EZ-Fill Becomes an Internationally Recognized Standard Platform for RTU Sterile Containers
Ompi, the company within Stevanato Group specialized in glass primary packaging for the pharmaceutical industry, has signed a license agreement with Gerresheimer. The agreement…
Ompi EZ-Fill Becomes an Internationally Recognized Standard Platform for RTU Sterile Containers
Ompi, the company within Stevanato Group specialized in glass primary packaging for the pharmaceutical industry, has signed a license agreement with Gerresheimer. The agreement…
Accelerating Development of Enabled Formulations for Poorly Soluble Drugs
Efficacy issues due to inadequate gastrointestinal (GI) absorption caused by insufficient aqueous solubility are encountered in up to 70% of new drugs in development. Often…
Capnia Completes Merger With Essentialis, Creating Rare Disease Therapeutics Company
Capnia, Inc., focused on the development and commercialization of novel therapeutics for the treatment of rare diseases, recently announced it has completed its previously announced…
Head & Neck Cancer Market Offers Fertile Investment Ground as Disease Understanding Improves
A substantial number of first-in-class products in the head and neck cancer pipeline will reach the market over the coming decade, potentially transforming the clinical…
Accelerating Development of Enabled Formulations for Poorly Soluble Drugs
Efficacy issues due to inadequate gastrointestinal (GI) absorption caused by insufficient aqueous solubility are encountered in up to 70% of new drugs in development. Often…
Capnia Completes Merger With Essentialis, Creating Rare Disease Therapeutics Company
Capnia, Inc., focused on the development and commercialization of novel therapeutics for the treatment of rare diseases, recently announced it has completed its previously announced…
Head & Neck Cancer Market Offers Fertile Investment Ground as Disease Understanding Improves
A substantial number of first-in-class products in the head and neck cancer pipeline will reach the market over the coming decade, potentially transforming the clinical…
Kitov Announces License Agreement for KIT-302 in South Korea
Kitov Pharmaceuticals Holdings Ltd., an innovative biopharmaceutical company, recently announced it has signed a definitive License Agreement for its lead product candidate, KIT-302, which was…
Kitov Announces License Agreement for KIT-302 in South Korea
Kitov Pharmaceuticals Holdings Ltd., an innovative biopharmaceutical company, recently announced it has signed a definitive License Agreement for its lead product candidate, KIT-302, which was…
Mithra Agrees to Exclusive Long-Term Agreement With Mayne Pharma
Mithra Pharmaceuticals recently announced an exclusive long-term license and supply agreement that extends beyond 10 years with Mayne Pharma, a leading specialty pharmaceutical company, for…
Japanese Pharmaceutical Market to Rise to $72 billion by 2021
The pharmaceutical market in Japan is set to rise from around $70 billion in 2016 to $72 billion by 2021, representing a low compound annual…
Advaxis & SELLAS Announce Licensing Agreement for Antigen-Targeting Immunotherapy
Advaxis, Inc. and SELLAS Life Sciences Group recently announced that Advaxis has granted SELLAS a license to develop a novel cancer immunotherapy agent using Advaxis’…
International Stem Cell Corporation Announces Third Patient With Parkinson's Disease in Clinical Trial
International Stem Cell Corporation recently announced the third patient in the clinical trial for Parkinson's Disease was successfully transplanted with ISC-hpNSC cells and is already…
Checkpoint Therapeutics Announces Issuance of US Composition of Matter Patent for Lung Cancer Compound
Checkpoint Therapeutics, Inc. recently announced that the US Patent and Trademark Office has issued a composition of matter patent for CK-101 (also known as RX518),…
Aclaris Therapeutics Submits NDA for Seborrheic Keratosis
Aclaris Therapeutics, Inc. recently announced it has submitted a New Drug Application (NDA) to the US FDA for A-101 40% topical solution (A-101) as a…
Essen BioScience to be Acquired for $320 Million
Essen BioScience Inc., a pioneer and leader in the field of cell-based assays and instrumentation used for drug discovery and basic research applications, recently signed…
nLife Therapeutics Enters Research Collaboration With WAVE Life Sciences
nLife Therapeutics S.L. recently announced the initiation of a research collaboration aimed at exploring cell-specific targeting of nucleic-acid therapeutics in the central nervous system (CNS)…
Gerresheimer AG Appoints New CEO
Dr. Christian Fischer will join the Management Board of Gerresheimer AG as an ordinary member on August 1, 2017 before taking over as Chief Executive…
